CATALYSTSeekingAlpha • 16h ago
FOMO Rally: Top 5 Stocks To Buy Ahead Of 2026 MidtermsAI and chip stocks are in focus as midterm election history points to a potential year-end rally. Discover 5 stocks positioned for growth.
Why NUTX Stock slipped -1.19% Today — RQD Quant Desk Flash
$210.10 -1.19% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $210.15
Nutex Health Inc. (NUTX) earns a Roarable Rating of B (Buy) with 75/100 RQD Confidence. High-quality cash engine (51% profit margin, 85% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.
ROARABLE B • BUY
Cap $1.44B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on NUTX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is NUTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-01, Nutex Health Inc. (NASDAQ: NUTX) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 75/100 at a spot price of $210.10 (-1.19% 1D, market cap $1.44B). Pillar breakdown: Fundamental Cash Engine 19/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 19/20. Across 1011 tracked Consumer Discretionary issuers, NUTX ranks #84 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does NUTX compare to LQDT and RDWR in the Consumer Discretionary sector?
▼
Within the Consumer Discretionary sector (Business Services), NUTX carries a Roarable B (75/100 RQD), trailing P/E of 20.3x, gross margin of 50.8%, and ROIC of 85.0%. By comparison, LQDT (Liquidity Services Inc.) holds a B grade (72/100 RQD, P/E 50.5x, ROIC 12.9%, cap $1.42B) and RDWR (Radware Ltd.) posts a D grade (47/100 RQD, P/E 76.5x, ROIC 3.7%, cap $1.55B). Among the 5-stock peer group, NUTX leads on earnings multiple (20.3x) while NUTX leads on capital efficiency (85.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for NUTX?
▼
Per NUTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001479681), Nutex Health Inc. generated $875.3M in revenue (+82.4% YoY), $70.8M in net income, and $245.6M in free cash flow against $918.5M in total assets and $29.2M in total debt. Key quantitative strengths: Strong cash generator (51% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $210.16 (+0.03%)🧬 Cannibal Buyback (-3.20% YoY Shares)⚙️ Cash Engine: 19/20 (A+) • 28.1% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 75/100 (B) historically ranked in the Top 12% of excess returns over the next 90 days (+7.4% avg 90D alpha vs SPY • 69.7% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERBUY • B
3-of-3 JEV AI Jury Bullish
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw B · Rk B+
Each axis scored 0–20
12M PRICE TARGET CONE+7.6% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NUTX)Realized 20D OHLCV Swing Band: ±11.7%
Deterministic 5-Pillar Attribution (75/100 Composite)
🔍 WHY NUTX SCORES 75/100 (B) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+19/20 pts (25% of score)
SEC XBRL FY 2025 (10-K): 28.1% FCF Margin ($245.6M FCF) & 50.8% Gross Margin
▲ #2 Bullish Driver: Insider Conviction & Share Dilution+19/20 pts (25% of score)
SEC Form 4 / 13F Thermometer: 86% Net Buy • Cannibal Buyback (-3.20% YoY Shares)
▼ #1 Drag / Risk Factor: Whale & Options Positioning6/20 pts (-14 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-14 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade B-$206.29-9.8% Next Q
67
Q2 (-2Q)Grade B$186.10+12.6% Next Q
70
Q3 (-1Q)Grade B$209.59+0.2% Next Q
72
CurrentGrade B$210.10+7.4% Hist 90D α
75
Trajectory: B- (67) → B (75)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the NUTX Bull Thesis Could Fail
Even with a 75/100 (B) score, NUTX faces multiple-compression risk if 20.3x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Broader market pullbacks can still drag down strong stocks in the short run.
⚠️ Forensic Kill-Switch #2
Dilution & Margin Drag: Cannibal Buyback (-3.20% YoY Shares) — any gross margin slip below 48.3% triggers an automatic RQD downgrade.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($203.24) or 200D SMA ($150.44) invalidates the momentum regime and cuts Target Base ($226.17) toward Bear Floor ($172.28).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $NUTX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “NUTX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why NUTX Stock slipped -1.19% Today — RQD Quant Desk Flash
Nutex Health Inc. (NUTX) slipped -1.19% to $210.10, trading at 89% of its 52-week range ($83.99 – $226.16). High-quality cash engine (51% profit margin, 85% return on capital) with steady institutional support.
- ▸Technical Tape: Trading at 89% of its 52-week range ($83.99 – $226.16) with RSI-14 at 46.7 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±11.7% around $210.10 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable B (Buy) backed by 50.8% gross margin and $245.6M annual free cash flow.
Live NUTX Headlines & Catalysts
MARKET WIREBenzinga • 6d ago
Ladenburg Thalmann Initiates Coverage On Nutex Health with Buy Rating, Announces Price Target of $336Ladenburg Thalmann analyst Jeffrey Cohen initiates coverage on Nutex Health (NASDAQ:NUTX) with a Buy rating and announces Price Target of $336.
MARKET WIREYahoo • 13d ago
Nutex Health Schedules 2026 Third Quarter Financial Results Release and Conference CallNutex Health, Inc. (NASDAQ: NUTX), a physician-led, integrated healthcare delivery system comprised of 28 state-of-the-art micro hospitals and hospital outpatient departments in 12 states and primary care-centric, risk-b
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk
Scheduled RQD Strong Buys & Whale Accumulation Briefing (NUTX Tape Review)
- ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
- ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
- ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
NUTX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +76.26%▲ ASCENDING CHANNEL
2026-10-30O $208.3H $210.2L $195.2C $210.1VOL 119.5K
RES: $254.2SUP: $191.4SMA50: $203.2SMA200: $150.4
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
NUTX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
13.9%/yr Implied 5Y Growth
vs. +82.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on NUTX today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for NUTX. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for NUTX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NUTX)
Consumer Discretionary Rank #84 of 1011
⚔️ LQDT vs NUTX Full Matrix →
1. Head-to-Head Consumer Discretionary Peer Comparison (NUTX vs. LQDT, RDWR, RSKD, AHG)
Industry: Business Services (90 Tracked Issuers)Across 1011 tracked Consumer Discretionary securities in the Roarable RQD universe, Nutex Health Inc. (NUTX) ranks #84 by composite RQD confidence (75/100, grade B) and #465 by equity capitalization ($1.44B). Within this direct 5-issuer industry benchmark cohort, NUTX leads on earnings valuation at 20.3x trailing P/E, while NUTX leads on capital efficiency and profitability with 85.0% ROIC and 50.8% gross margin. NUTX currently leads its immediate peer cohort in composite quantitative strength at 75/100 (B).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| NUTX
ACTIVE
Nutex Health Inc. | B | 75/100 | 20.3x | 50.8% | 85.0% | -1.19% | $1.44B | Benchmark Subject |
| LQDT Liquidity Services Inc. | B | 72/100 | 50.5x | 43.8% | 12.9% | +3.32% | $1.42B | /lqdt-vs-nutx → |
| RDWR Radware Ltd. | D | 47/100 | 76.5x | 80.7% | 3.7% | -1.40% | $1.55B | /rdwr-vs-nutx → |
| RSKD Riskified Ltd. (Class A) | D+ | 53/100 | — | 51.7% | -20.3% | -0.55% | $1.22B | /rskd-vs-nutx → |
| AHG Akso Health Group ADS | D- | 41/100 | — | -0.1% | — | +2.31% | $1.14B | /ahg-vs-nutx → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001479681In its most recent audited fiscal period (FY2025, filed 2025-12-31), Nutex Health Inc. (NUTX) reported GAAP revenue of $875.3M (+82.4% vs. FY2024 revenue of $479.9M , and +253.4% cumulative change since FY2023) , GAAP net income of $70.8M, operating cash flow of $248.1M, and free cash flow of $245.6M (+1078.0% YoY). On the balance sheet, NUTX closed FY2025 with $918.5M in total assets against $29.2M in total debt (Altman Z-Score: 3.75, Piotroski F-Score: 9/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $875.3M | $70.8M | $248.1M | $245.6M | $918.5M | $29.2M |
| FY2024 (FY) | 2024-12-31 | $479.9M | $52.1M | $23.2M | $20.8M | $655.3M | $22.5M |
| FY2023 (FY) | 2023-12-31 | $247.6M | -$45.8M | $1.3M | $1.3M | — | — |
3. NUTX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs NUTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Nutex Health Inc. (NASDAQ: NUTX) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 75/100 at a spot price of $210.10 (-1.19% 1D, market cap $1.44B). Pillar breakdown: Fundamental Cash Engine 19/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 19/20. Across 1011 tracked Consumer Discretionary issuers, NUTX ranks #84 in composite RQD confidence.
How does NUTX compare to LQDT and RDWR in the Consumer Discretionary sector?
Within the Consumer Discretionary sector (Business Services), NUTX carries a Roarable B (75/100 RQD), trailing P/E of 20.3x, gross margin of 50.8%, and ROIC of 85.0%. By comparison, LQDT (Liquidity Services Inc.) holds a B grade (72/100 RQD, P/E 50.5x, ROIC 12.9%, cap $1.42B) and RDWR (Radware Ltd.) posts a D grade (47/100 RQD, P/E 76.5x, ROIC 3.7%, cap $1.55B). Among the 5-stock peer group, NUTX leads on earnings multiple (20.3x) while NUTX leads on capital efficiency (85.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for NUTX?
Per NUTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001479681), Nutex Health Inc. generated $875.3M in revenue (+82.4% YoY), $70.8M in net income, and $245.6M in free cash flow against $918.5M in total assets and $29.2M in total debt. Key quantitative strengths: Strong cash generator (51% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is NUTX trading relative to its 50-day, 200-day, and 52-week technical levels?
NUTX last traded at $210.10 (-1.19% on volume of 79,605 shares), positioning the stock +3.38% above its 50-day simple moving average ($203.24) and +39.66% above its 200-day simple moving average ($150.44). Across its 52-week range of $83.99 to $226.16, NUTX sits at the 88.7% percentile with a 14-day RSI of 46.7 (NEUTRAL RANGE) and an implied next-earnings move of ±11.7% ($185.52 to $234.68).
NUTX Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is NUTX stock moving today?
Why NUTX Stock slipped -1.19% Today — RQD Quant Desk Flash. High-quality cash engine (51% profit margin, 85% return on capital) with steady institutional support.